Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Blood (2023) 142 (Supplement 1): 5907.

https://doi.org/10.1182/blood-2023-179168

Published: 2023

Journal Articles

Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

Paolo Strati, Tae Min Kim, Alexey V Danilov, Chan Y. Cheah, Dok Hyun Yoon, Wojciech Jurczak, Shringi Sharma, Jeong Lim Yoon, Serena Arduini, Jamal Saeh, Richard F. Olsson, Gareth Gregory

Blood (2022) 140 (Supplement 1): 6656–6658.

https://doi.org/10.1182/blood-2022-165979

Published: 2022

Journal Articles

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

Shukaib Arslan, Shaun Fleming, Nitin Jain, Giovanni Martinelli, Anthony S. Stein, James S. Blachly, Ashish Bajel, Antonio Curti, Giovanni Marconi, Giulia Fabbri, Yotvat Marmor, Shringi Sharma, Nairouz Elgeioushi, Natalia Couto-Francisco, Jamal Saeh, Raoul Tibes, Fathima Zumla Cader, Marina Konopleva

Blood (2022) 140 (Supplement 1): 9091–9093.

https://doi.org/10.1182/blood-2022-166192

Published: 2022

Journal Articles

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study

Tim H. Brummendorf, Patrick Medd, Raphael Koch, Stephan Stilgenbauer, Shringi Sharma, Yun He, Stefanie Meyer, Margaret C. Wey, Jamal Saeh, Richard F. Olsson, Arnon P. Kater

Blood (2022) 140 (Supplement 1): 3126–3127.

https://doi.org/10.1182/blood-2022-167203

Published: 2022

Journal Articles

NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

Marina Konopleva, Nitin Jain, Courtney L Andersen, Natalia Couto Francisco, Nairouz Elgeioushi, Rosalind Hobson, Martin Scott, John Stone, Shringi Sharma, Pablo Morentin Gutierrez, Raoul Tibes, Barry Davies, Thomas Winkler, Giulia Fabbri, Fathima Zumla Cader, Nicole McNeer

Blood (2021) 138 (Supplement 1): 2353.

https://doi.org/10.1182/blood-2021-147482

Published: 2021

Journal Articles

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Mark Roschewski, Veerendra Munugalavadla, Barrett Nuttall, Kathleen Burke, Melih Acar, Rafael White, Maria Udriste, Shringi Sharma, Brian Dougherty, Ian Flinn, Nakhle S. Saba, Patrick M. Reagan, Sven de Vos, Hendrik-Tobias Arkenau, Graham P. Collins, Andrew Mortlock, Manish R. Patel

Blood (2021) 138 (Supplement 1): 1418.

https://doi.org/10.1182/blood-2021-147567

Published: 2021

Journal Articles

New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS)

Shringi Sharma, Xavier Pepin, Harini Burri, Lianqing Zheng, Nataliya Kuptsova-Clarkson, Anouk de Jong, Ting Yu, Holly L MacArthur, Michal Majewski, Joseph A Ware, James Mann, David Ramies, Veerendra Munugalavadla, Louise Sheridan, Helen Tomkinson

Blood (2021) 138 (Supplement 1): 4365.

https://doi.org/10.1182/blood-2021-146610

Published: 2021

Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

Vinay Manu Daryani, PharmD, Shringi Sharma, PhD, Guan Xing, PhD, Jeffrey Silverman, PhD, Adeboye Henry Adewoye, MD, Anita Mathias, PhD

Blood (2017) 130 (Supplement 1): 5344.

https://doi.org/10.1182/blood.V130.Suppl_1.5344.5344

Published: 2017

Journal Articles

Exposure-Response of Entospletinib (ENTO) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Sneha Gupta, PhD, Amy Meng, PhD, Shringi Sharma, PhD, Wei Ye, PhD, Jeffrey Silverman, PhD, Esteban M. Abella, MD, Anita Mathias, PhD

Blood (2017) 130 (Supplement 1): 1735.

https://doi.org/10.1182/blood.V130.Suppl_1.1735.1735

Published: 2017

Journal Articles

Preclinical Modeling of ACVR1-Dependent Hepcidin Production and Anemia By Momelotinib

Matthew Warr, Malte Asshoff, Jim Zheng, Shringi Sharma, Pat Maciejewski, Guenter Weiss, Igor Theurl, J. Andrew Whitney

Blood (2016) 128 (22): 1967.

https://doi.org/10.1182/blood.V128.22.1967.1967

Published: 2016

Journal Articles

Phase 1b and Pharmacokinetic Study of Idelalisib in Japanese Patients with Relapsed or Refractory (R/R) Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Tomohiro Kinoshita, MD PhD, Noriko Fukuhara, MD PhD, Hirokazu Nagai, MD PhD, Koji Izutsu, MD, Yukio Kobayashi, MD PhD, Yusuke Higuchi, MD, Hideo Harigae, MD, Takashi Tokunaga, MD PhD, Henry Adewoye, MD, Michelle Robeson, ND, Shringi Sharma, PhD, Masato Fukui, MD, Jie Gao, PhD, Christine Christenson, Kensei Tobinai, MD PhD

Blood (2015) 126 (23): 5089.

https://doi.org/10.1182/blood.V126.23.5089.5089

Published: 2015

Journal Articles

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Shringi Sharma, PhD, Ying Guo, PhD, Feng Jin, PhD, Xiaoming Li, PhD, Ronald L. Dubowy, MD, Terry Newcomb, PhD, Srini Ramanathan, PhD

Blood (2015) 126 (23): 4172.

https://doi.org/10.1182/blood.V126.23.4172.4172

Published: 2015

NARROW

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial

Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematological Malignancies. Preliminary Results from an Ongoing Phase I/II Trial

Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study

NIMBLE: A Phase I/II Study of AZD0466 Monotherapy or in Combination in Patients with Advanced Hematological Malignancies

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS)

Exposure-Response of Idelalisib Administered in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Chronic Lymphocytic Leukemi

Exposure-Response of Entospletinib (ENTO) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Preclinical Modeling of ACVR1-Dependent Hepcidin Production and Anemia By Momelotinib

Phase 1b and Pharmacokinetic Study of Idelalisib in Japanese Patients with Relapsed or Refractory (R/R) Indolent B-Cell Non-Hodgkin Lymphoma (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Exposure-Response of Idelalisib Administered in Combination with Ofatumumab for the Treatment of Relapsed Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only